Nuvalent to Participate in Upcoming September Investor Conferences

On August 31, 2023 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the following September investor conferences (Press release, Nuvalent, AUG 31, 2023, View Source [SID1234634816]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2023 Wells Fargo Securities Healthcare Conference on Friday, September 8, 2023 at 10:15 a.m. ET in Boston;
Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 a.m. ET in NYC.
Live webcasts will be available in the investor section of the company’s website at www.nuvalent.com, and archived for 30 days following the presentations.